Regenron’s drug to treat a type of blood cancer gets US regulator’s nod
HQ Team June 3, 2025: Regeneron Pharmaceuticals, Inc.’s drug for a type of blood cancer in patients who have received four treatments before,.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team June 3, 2025: Regeneron Pharmaceuticals, Inc.’s drug for a type of blood cancer in patients who have received four treatments before,.
fizer Inc.’s combination drug to treat a type of metastatic colorectal cancer has been approved by the US drug regulator, according to a.
Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to.
HQ Team August 11, 2023: The USFDA has granted accelerated approval to Janssen Pharmaceutical Companies for its cancer antibody treatment, Talvey, to treat.